search icon
lixt-img

Lixte Biotechnology Holdings Inc, Common Stock

LIXT

NAQ

$2.5

+$0.09

(3.73%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$5.62M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
9.64K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.17
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.31 L
$4.4 H
$2.5

About Lixte Biotechnology Holdings Inc, Common Stock

LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameLIXTSectorS&P500
1-Week Return4.15%0.31%-1.26%
1-Month Return19.05%0.6%-4.16%
3-Month Return41.24%-9.44%-0.46%
6-Month Return3.73%-5.15%3.58%
1-Year Return38.89%0.33%22.47%
3-Year Return-87.24%4.53%25.13%
5-Year Return-93.95%35.98%77.7%
10-Year Return-72.22%100.72%190.12%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Profit-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Margin-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses2.49M3.27M6.72M6.31M5.09M[{"date":"2019-12-31","value":37.05,"profit":true},{"date":"2020-12-31","value":48.6,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":93.91,"profit":true},{"date":"2023-12-31","value":75.74,"profit":true}]
Operating Income(2.49M)(3.27M)(6.72M)(6.31M)(5.09M)[{"date":"2019-12-31","value":-249006600,"profit":false},{"date":"2020-12-31","value":-326644000,"profit":false},{"date":"2021-12-31","value":-672044500,"profit":false},{"date":"2022-12-31","value":-631148100,"profit":false},{"date":"2023-12-31","value":-509023600,"profit":false}]
Total Non-Operating Income/Expense99.45K3.12K(14.74K)1.27K14.01K[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":3.13,"profit":true},{"date":"2021-12-31","value":-14.82,"profit":false},{"date":"2022-12-31","value":1.27,"profit":true},{"date":"2023-12-31","value":14.08,"profit":true}]
Pre-Tax Income(2.44M)(3.26M)(6.73M)(6.31M)(5.09M)[{"date":"2019-12-31","value":-244034300,"profit":false},{"date":"2020-12-31","value":-326488200,"profit":false},{"date":"2021-12-31","value":-672839600,"profit":false},{"date":"2022-12-31","value":-631253500,"profit":false},{"date":"2023-12-31","value":-508702900,"profit":false}]
Income Taxes(49.72K)(1.56K)6.79K(7.82K)(5.09K)[{"date":"2019-12-31","value":-732.51,"profit":false},{"date":"2020-12-31","value":-22.95,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-115.22,"profit":false},{"date":"2023-12-31","value":-74.99,"profit":false}]
Income After Taxes(2.39M)(3.26M)(6.74M)(6.30M)(5.08M)[{"date":"2019-12-31","value":-239062000,"profit":false},{"date":"2020-12-31","value":-326332400,"profit":false},{"date":"2021-12-31","value":-673518400,"profit":false},{"date":"2022-12-31","value":-630471400,"profit":false},{"date":"2023-12-31","value":-508193876,"profit":false}]
Income From Continuous Operations(2.44M)(3.26M)(6.73M)(6.31M)(5.69M)[{"date":"2019-12-31","value":-244034300,"profit":false},{"date":"2020-12-31","value":-326488200,"profit":false},{"date":"2021-12-31","value":-672839600,"profit":false},{"date":"2022-12-31","value":-631253500,"profit":false},{"date":"2023-12-31","value":-568607800,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(2.39M)(3.26M)(6.74M)(6.30M)(5.09M)[{"date":"2019-12-31","value":-239062000,"profit":false},{"date":"2020-12-31","value":-326332400,"profit":false},{"date":"2021-12-31","value":-673518400,"profit":false},{"date":"2022-12-31","value":-630471400,"profit":false},{"date":"2023-12-31","value":-508702900,"profit":false}]
EPS (Diluted)(0.07)(0.24)(0.51)(0.41)(2.03)[{"date":"2019-12-31","value":-7.43,"profit":false},{"date":"2020-12-31","value":-24,"profit":false},{"date":"2021-12-31","value":-51,"profit":false},{"date":"2022-12-31","value":-40.8,"profit":false},{"date":"2023-12-31","value":-203.34,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

LIXT
Cash Ratio 4.98
Current Ratio 5.13

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

LIXT
ROA (LTM) -87.33%
ROE (LTM) -163.33%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

LIXT
Debt Ratio Lower is generally better. Negative is bad. 0.19
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.81

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

LIXT
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 12.00
Price/FCF NM
EV/R 0.00
EV/Ebitda NM
PEG NM

FAQs

What is Lixte Biotechnology Holdings Inc share price today?

Lixte Biotechnology Holdings Inc (LIXT) share price today is $2.5

Can Indians buy Lixte Biotechnology Holdings Inc shares?

Yes, Indians can buy shares of Lixte Biotechnology Holdings Inc (LIXT) on Vested. To buy Lixte Biotechnology Holdings Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in LIXT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Lixte Biotechnology Holdings Inc be purchased?

Yes, you can purchase fractional shares of Lixte Biotechnology Holdings Inc (LIXT) via the Vested app. You can start investing in Lixte Biotechnology Holdings Inc (LIXT) with a minimum investment of $1.

How to invest in Lixte Biotechnology Holdings Inc shares from India?

You can invest in shares of Lixte Biotechnology Holdings Inc (LIXT) via Vested in three simple steps:

  • Click on Sign Up or Invest in LIXT stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Lixte Biotechnology Holdings Inc shares
What is Lixte Biotechnology Holdings Inc 52-week high and low stock price?

The 52-week high price of Lixte Biotechnology Holdings Inc (LIXT) is $4.4. The 52-week low price of Lixte Biotechnology Holdings Inc (LIXT) is $1.31.

What is Lixte Biotechnology Holdings Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Lixte Biotechnology Holdings Inc (LIXT) is

What is Lixte Biotechnology Holdings Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Lixte Biotechnology Holdings Inc (LIXT) is 12.00

What is Lixte Biotechnology Holdings Inc dividend yield?

The dividend yield of Lixte Biotechnology Holdings Inc (LIXT) is 0.00%

What is the Market Cap of Lixte Biotechnology Holdings Inc?

The market capitalization of Lixte Biotechnology Holdings Inc (LIXT) is $5.62M

What is Lixte Biotechnology Holdings Inc’s stock symbol?

The stock symbol (or ticker) of Lixte Biotechnology Holdings Inc is LIXT

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top